Therapeutic Areas Under Development
ZeeVieZee Bio Pharma is actively engaged in research and development programs across multiple therapeutic areas, with a focus on addressing unmet clinical needs. The company’s current development pipeline encompasses cardiovascular disorders, oral mucositis, neurological diseases, and gastroenterological conditions. These programs are directed toward the development of differentiated pharmaceutical formulations designed to support improved therapeutic outcomes, patient acceptability, and potential clinical utility.
Completed Product Development Programs
ZEEVIEZEE has successfully completed formulation and product development activities for selected pharmaceutical products spanning non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, selective serotonin–norepinephrine reuptake inhibitors (SNRIs), and anti-inflammatory therapies. The completed development programs reflect the company’s capabilities in formulation optimization, pharmaceutical development, analytical characterization, and preparation of products for subsequent regulatory and clinical development pathways.
Planned Clinical Development
Following completion of the necessary preclinical, formulation, analytical, and regulatory development activities, clinical trials for selected ZEEVIEZEE products are planned to commence from the fourth quarter (Q4) of 2027, subject to applicable regulatory approvals and clinical-trial requirements. The transition into clinical development represents an important milestone in advancing the company’s pharmaceutical candidates from laboratory-scale development toward evaluation of their safety, tolerability, pharmacokinetic characteristics, and therapeutic potential in human subjects.
Topical Antidepressant Formulation for Oncology-Associated Pain
ZEEVIEZEE has completed the development of a topical formulation based on an antidepressant therapeutic approach, intended for investigation in the management of pain associated with oncology care, including patients undergoing chemotherapy. The formulation has been developed with an emphasis on localized drug delivery and patient-oriented administration. Further clinical evaluation will be required to establish its safety, efficacy, tolerability, and therapeutic benefit in the intended patient population.
Allergy Management Formulation
ZEEVIEZEE has also completed formulation development activities for a pharmaceutical product intended for the management of allergic conditions. The development program is progressing toward clinical evaluation, with clinical trials anticipated during Q4 2026–2027, subject to completion of applicable regulatory, ethical, and clinical-trial prerequisites. The program reflects ZEEVIEZEE’s focus on developing formulation-based therapeutic solutions that may address relevant patient and treatment needs.
Cardiovascular Drug Development and Regulatory Progress
ZEEVIEZEE’s cardiovascular drug development program has progressed to an important regulatory milestone, with a No Objection Certificate (NOC) reportedly obtained from the Central Drugs Standard Control Organisation (CDSCO) for the conduct of human studies. Based on the required regulatory and clinical prerequisites, initiation of clinical trials is planned for Q4 2026–2027.The clinical development program is intended to generate systematic evidence regarding the investigational product’s safety, tolerability, pharmacological characteristics, and potential therapeutic efficacy in the target population.